VivoSim Labs, Inc. (VIVS) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of VivoSim Labs, Inc. stock $0.12, price $0.12, that is 5.5% below the price, quality 31 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
VivoSim Labs, Inc.
VIVS · USThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.1237 – $96.36 · fair‑value band $0.0876 – $0.1461 · the $0.1237 price screens above the $0.1169 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether VivoSim Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
Show moreShow less
It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025.
VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Stock analysis
VivoSim Labs, Inc. (VIVS) currently trades at $0.1237, while our estimate is $0.1169, so the stock looks roughly fairly valued today (gap 5.8%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.0876 (bear) to $0.1461 (bull), the price of $0.1237 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
VivoSim Labs, Inc. reported revenue of $131K in FY2026 versus $1.5M in FY2022, a compound −45.6%/yr. Reported net income was −$13.8M in FY2026.
Key figures
Market cap $2.6M Micro · P/S ratio 23.0 · EPS (TTM) $−4.47 · Return on equity −343% · Return on assets (EBIT) −119% (5-year average) · Operating margin −10,117% · Revenue (TTM) $112K · Revenue growth (YoY) −51.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).
What moves the price
The share trades about 96% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −6%, VIVS screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $2,800, on Aug 31, 2026.
- BuyTony Serge LialinChief Commercial Officer10,000 shares at $0.2800$2,800Aug 31, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch VIVS, get fair value alerts →
Compare VivoSim Labs, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs VIVS |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs VIVS |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs VIVS |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs VIVS |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs VIVS |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs VIVS |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs VIVS |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs VIVS |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs VIVS |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs VIVS |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is VivoSim Labs, Inc. (VIVS) overvalued or undervalued?
What is the fair value of VIVS?
What is the quality score of VIVS?
What is the price target for VivoSim Labs, Inc. (VIVS)?
What is the VivoSim Labs, Inc. stock forecast for 2026?
What is the revenue of VivoSim Labs, Inc. (VIVS)?
What is the intrinsic value of VivoSim Labs, Inc. (VIVS)?
Is VivoSim Labs, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of VIVS?
How much is VivoSim Labs, Inc. worth?
What do the bullish and bearish scenarios say about VIVS?
How solid is the balance sheet of VivoSim Labs, Inc. (VIVS)?
How far is VIVS from its 52-week high?
Which stocks are comparable to VivoSim Labs, Inc.?
Is VivoSim Labs, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of VivoSim Labs, Inc. (VIVS)?
What should I pay attention to with VivoSim Labs, Inc. right now?
Key figures of VivoSim Labs, Inc.
How large is the market capitalisation of VivoSim Labs, Inc. (VIVS)?
What is the P/S ratio of VivoSim Labs, Inc. (VIVS)?
What are the earnings per share of VivoSim Labs, Inc. (VIVS)?
What is the return on equity of VivoSim Labs, Inc. (VIVS)?
What is the EBIT return on assets of VivoSim Labs, Inc. (VIVS)?
What is the operating margin of VivoSim Labs, Inc. (VIVS)?
How fast is revenue growing at VivoSim Labs, Inc. (VIVS)?
How much free cash flow does VivoSim Labs, Inc. (VIVS) generate?
How much net cash does VivoSim Labs, Inc. (VIVS) hold?
Watch VivoSim Labs, Inc. in the live analysis
One click puts VivoSim Labs, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.